Advanced Enzyme Technologies Ltd (ADVENZYMES) — shareholding pattern, promoter holding, financials and share price
About Advanced Enzyme Technologies Ltd (ADVENZYMES)
Advanced Enzyme Technologies Ltd operates in the Biotechnology industry, within the Healthcare sector. It trades on the NSE as ADVENZYMES and on the BSE under scrip code 540025. Its ISIN is INE837H01020.
Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes. [1]
Advanced Enzyme Technologies Limited is the largest Indian enzyme company, specializing in manufacturing and selling enzyme-based solutions across various industries such as human health care, animal nutrition, and food processing.
For the third quarter of FY26, the company's revenue grew by 2% year-on-year, showcasing stability despite challenging market conditions.
Listed peers in Biotechnology: Gufic BioSciences Ltd, SMS Pharmaceuticals Ltd, Novartis India Ltd, Aarti Drugs Ltd, Morepen Laboratories Ltd, Panacea Biotec Ltd.
Valuation & Returns
10 Jul 2026At ₹329.7 a share on 10 Jul 2026, Advanced Enzyme Technologies Ltd (ADVENZYMES) was valued at a price-to-earnings ratio of 21.27x against an industry P/E of 36.41x and a price-to-book of 2.6x on a book value of ₹126.89 per share as of Mar 2025. Solomo computes return on equity of 12.22% and return on capital employed of 16.1% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 21.27x
- Industry P/E
- 36.41x
- P/B
- 2.6x
- EPS (TTM)
- ₹15.5
- Book value / share
- ₹126.89
- ROE
- 12.22%
- ROCE
- 16.1%
- ROA
- 10.71%
- Debt / equity
- 0.03x
- Dividend yield
- 0.36%
- EBITDA margin
- 36.91%
- 52-week range
- ₹251.9 – ₹419.8
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Advanced Enzyme Technologies Ltd (ADVENZYMES) reported revenue of ₹746 crore, net profit of ₹174 crore and earnings per share of ₹15.07. That compares with revenue of ₹637 crore and net profit of ₹134 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹203 crore and net profit ₹45 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 529 | 541 | 624 | 637 | 746 |
| Net profit (₹ cr) | 124 | 104 | 137 | 134 | 174 |
| EPS (₹) | 10.7 | 9.45 | 11.92 | 11.72 | 15.07 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 10.54% | 9.82% | 13.27% | 17.09% |
| Profit growth | 16.03% | 13.17% | 33.40% | 29.59% |
| Stock price CAGR | - | -5% | 4% | -1% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 43.24% of Advanced Enzyme Technologies Ltd (ADVENZYMES) (down 0.02 pp QoQ), foreign institutional investors (FII) hold 26.71% and domestic institutional investors (DII) hold 4.78%. Market capitalisation was ₹3,692 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2016.
Largest disclosed public shareholders in Jun 2026: Orbimed Asia III Mauritius FVCI Limited 12.06%, Nalanda India Equity Fund Limited 8.45%, Polunin Emerging Markets Small Cap Fund, LLC 2.46%, Clarus Capital I 2.28%, Marval Guru Fund 1.79%, Pradip Bhailal Shah 1.66%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 43.24% | - | 26.71% | 4.78% | 56.76% |
| Mar 2026 | 43.26% | - | 25.49% | 5.41% | 56.74% |
| Dec 2025 | 43.04% | - | 25.86% | 5.51% | 56.96% |
| Sep 2025 | 43.07% | - | 25.41% | 6.41% | 56.93% |
| Jun 2025 | 43.08% | - | 23.46% | 8.45% | 56.92% |
| Mar 2025 | 43.08% | - | 11.9% | 8.19% | 56.92% |
| Dec 2024 | 42.93% | - | 12.58% | 8.18% | 57.07% |
| Sep 2024 | 42.95% | - | 12.63% | 8.02% | 57.05% |